Conventional drug delivery systems targeting gastrointestinal diseases suffer from systemic distribution inefficiencies, leading to suboptimal therapeutic concentrations at disease loci and the risk of systemic side effects. In contrast, magnetic soft robots, by virtue of their diminutive size and wireless control, offer a promising tether-free modality to navigate and perform localized drug release within the GI environment. However, the intricate spatial constraints and dynamic nature of the GI tract pose significant hurdles for existing robots, which often lack the flexibility in structural reconfiguration and precise magnetization required for safe and effective operation.

The novel magnetic soft sheet robot is conceived as a four-layered fully soft structure, ingeniously combining two outer linear low-density polyethylene (LLDPE) layers sandwiching a core layer of magnetorheological fluids (MRFs), further reinforced by a polyamide nylon mesh for mechanical support. Measuring a compact 30 mm in length, 10 mm in width, and only 1.5 mm in thickness, this featherlight device weighs a mere 0.55 grams. Notably, it remains demagnetized in zero external magnetic fields, thereby preventing inadvertent activation or interference within the human body.

A remarkable technical hallmark of this system lies in its ability for real-time reconfigurable magnetization and reversible folding. The embedded magnetorheological fluid core responds to external magnetic fields by rapidly forming aligned chains of magnetic particles within milliseconds. This dynamic internal magnetization vector is finely steerable through a sophisticated five-degree-of-freedom magnetic field platform, enabling precise and reversible folding maneuvers. By contracting to roughly one-third of its unfolded surface area, the robot effortlessly maneuvers through constricted intestinal passages, subsequently unfolding to maximize surface contact in the gastric cavity for stable locomotion and drug delivery.

Empirical validation involved fabricating five distinct prototypes varying in magnetorheological fluid density from 3.0 to 4.2 g/mL, to optimize responsiveness and mechanical stability. Comprehensive in vitro experiments demonstrated robust locomotion capabilities including controlled flipping, steering, and calibrated folding on diverse substrates such as smooth, soft, inclined, and submerged surfaces. Impressively, the robot maintained reliable functional performance even while burdened with biodegradable hydrogel drug loads approximately 30% of its own weight, underscoring its therapeutic delivery viability.

To simulate real-world biomedical scenarios, the team conducted rigorous ex vivo trials using porcine stomach models that closely emulate human gastric anatomy and physiology. Across ten repeated trials, the robot demonstrated exceptional precision in navigating toward predesignated lesion sites within an average timeframe of just five minutes. Upon reaching target regions, it securely adhered to the mucosal surface, releasing hydrogel-embedded drugs which disintegrated over 30 minutes, ensuring localized, sustained therapeutic delivery. Complementary ultrasonic imaging with Voluson E10 technology tracked the robot’s autonomic movement within the closed stomach cavity, affirming the system’s controllability and continuous monitoring feasibility in vivo.

Recognizing the crucial importance of biocompatibility, exhaustive assessments were performed by immersing the robot in simulated gastric (pH 1.2) and intestinal (pH 6.8) fluids at physiological temperature for 24 hours. No structural degradation, swelling, or deformation was observed, indicating robust material resilience. Chemical analyses confirmed the absence of hazardous leachates beyond safety thresholds, and microbiological cultures revealed no bacterial contamination, collectively verifying the robot’s suitability for safe human deployment without toxicological or infectious risks.

Beyond the immediate leap in functional design, this magnetic soft sheet robot exemplifies transformative advances in magnetorheological soft robotics, overcoming entrenched technical impediments related to adaptability and magnetization control. Boasting a fully soft, untethered configuration that offers superb targeting accuracy and operational dexterity, it stands poised to redefine noninvasive therapeutic interventions for gastrointestinal diseases, facilitating precise drug delivery with minimal patient discomfort or risk.

Looking forward, efforts to enhance the robot’s integration with clinical workflows will prioritize improving magnetic actuation and control mechanisms to overcome the challenges posed by acidic stomach environments, intrinsic GI motility, and fluid dynamics. Moreover, enhancing the synergy between magnetic field manipulation and ultrasonic tracking will enable more refined, responsive clinical operations, potentially paving the way for autonomous in vivo navigation and real-time therapeutic modulation.

This forefront research reflects the convergence of engineering ingenuity and biomedical science, demonstrating how magnetorheological materials can be harnessed to create soft robotic systems that adaptively shape and orient themselves within complex physiological milieus. Through interdisciplinary collaboration, this platform represents a milestone toward realizing smart, minimally invasive medical devices capable of personalized, spatially precise drug administration deep within the human body.

As gastrointestinal diseases continue to pose significant global health burdens, innovations such as this magnetic soft sheet robot offer a beacon of hope, promising to improve treatment outcomes through localized, controlled therapy. The strategic blend of materials science, magnetic field engineering, and soft robotics not only exemplifies next-generation medical technology but also exemplifies the future trajectory of targeted therapeutic delivery solutions.

China University of Mining and Technology stands at the helm of this pioneering work, leveraging its robust engineering and biomedical research ecosystem to drive forward the development of intelligent, soft robotic systems. Under the leadership of researcher Xinhua Liu, whose expertise spans magnetic robotics and magnetorheological materials, the project leverages advanced multidisciplinary strategies to breach long-standing barriers and translate sophisticated lab innovations into practical clinical applications.

This pioneering robot is supported by prominent funding sources including the National Natural Science Foundation of China and the Jiangsu Provincial Science Foundation, underscoring the strategic importance attributed to advancing medical robotics technology. Continued research and optimization hold the potential to amplify the clinical impact of this technology, potentially revolutionizing minimally invasive interventions across a range of gastrointestinal pathologies.

In summation, the magnetic soft sheet robot with real-time reconfigurable magnetization epitomizes a technological tour de force, bridging soft material design, adaptive magnetic actuation, and biomedical engineering toward creating an agile, biocompatible drug delivery vehicle. Its ability to fold precisely and navigate the complex GI terrain, coupled with safe, localized therapeutic release monitored by ultrasonic imaging, opens promising avenues in targeted medicine, marking a transformative step for future robotic medical devices.

Subject of Research: Robotics, Soft Magnetic Robotics, Biomedical Engineering

Article Title: A Folding Magnetic Soft Sheet Robot With Real‐Time Reconfigurable Magnetization for Targeted Drug Delivery

News Publication Date: 21-Jan-2026

Web References: http://dx.doi.org/10.1002/smb2.70028

Image Credits: 2026 China University of Mining and Technology

Keywords

Magnetic Soft Robot, Magnetorheological Fluids, Real-time Reconfigurable Magnetization, Targeted Drug Delivery, Gastrointestinal Tract, Soft Robotics, Biomedical Engineering, Ultrasonic Tracking, Biocompatibility, Minimally Invasive Medicine

The core of the technology lies in the soft neural interface, fabricated from ultraflexible and biocompatible materials that conform intimately to the delicate tissues of the nervous system. Unlike rigid conventional implants, this interface seamlessly integrates with neural structures, minimizing tissue damage and inflammatory responses while maintaining stable signal acquisition and stimulation capabilities. The interface essentially functions as a bidirectional communication conduit, capable of detecting neural signals and simultaneously delivering therapeutic agents in response to physiological cues or external commands.

A remarkable feature of this system is the tapered peristaltic micropump, a microfabricated device miniaturized to the scale of neural implants yet powerful enough to move minute volumes of fluid with exquisite precision. The tapered design significantly enhances pumping efficiency by optimizing the deformation cycles that drive peristalsis, enabling the pump to deliver drugs in finely tuned doses directly to targeted sites. This peristaltic mechanism, inspired by smooth muscle movements in biological systems, ensures that the drug flow is smooth and pulsatile, preventing backflow and preserving drug integrity.

Wireless control constitutes a pivotal component in realizing the practical utility of this device. Traditional drug delivery methods involving tethered systems often restrict patient mobility and expose the implant to potential infection risks. By integrating wireless communication and power transfer modules, the research team achieved complete untethered operation. Patients or clinicians can remotely program the drug release schedules, adjusting dosages dynamically according to real-time physiological feedback. This wireless modality not only improves patient comfort and safety but also broadens the scope of adaptable, personalized therapeutic regimens.

The entire system is ingeniously encapsulated within a soft, stretchable substrate that safeguards the delicate electronic components while conforming to body movements. This mechanical compliance reduces the risk of device displacement or damage during daily activity, a common challenge faced by implantable devices. Moreover, the flexibility allows for implantation in challenging anatomical locations without causing discomfort or impairing natural function. These material innovations are critical to advancing the longevity and reliability of neural interfaces in chronic applications.

Fabrication techniques employed by the researchers combine microelectromechanical systems (MEMS) technology with innovative soft lithography and thin-film deposition processes. The micropump and electrodes are constructed from biocompatible polymers embedded with conductive nanomaterials, yielding a robust yet flexible architecture. Precision microfabrication ensures the micropump channels and valves operate efficiently at microscale dimensions, essential for the delicate control of drug volumes on the order of microliters or less. The integration of these components into a unified system embodies a sophisticated engineering feat that merges multiple disciplines.

From a physiological perspective, the ability to deliver drugs directly to neural tissue circumvents significant hurdles of systemic administration, such as blood-brain barrier penetration and off-target side effects. Targeted drug delivery enhances therapeutic efficacy by achieving higher local drug concentrations while minimizing systemic toxicity. This capability is particularly vital for treating complex neurological diseases like epilepsy, Parkinson’s disease, and chronic pain syndromes, where precise modulation of neural activity through pharmacological means can profoundly impact patient outcomes.

The functional synergy between neural sensing and drug delivery presents a leap towards closed-loop neuromodulation therapies. By continuously monitoring neural activity, the device can autonomously trigger drug release in response to abnormal neural patterns, effectively enabling smarter, adaptive therapies that respond instantaneously to disease dynamics. Such closed-loop systems herald a new horizon for precision medicine, where treatments are not only personalized but also temporally optimized to individual patient needs.

Furthermore, the power requirements of this soft neural interface have been meticulously minimized through energy-efficient electronics and smart circuit design. The wireless power transfer system employs inductive coupling optimized for low-power operation, ensuring prolonged device function without frequent battery replacements or surgeries. This energy-conscious design extends the applicability of the technology to chronic implantation scenarios, where device longevity is paramount for patient quality of life and clinical efficacy.

Beyond the immediate clinical impact, this technology opens avenues for fundamental neuroscience research by enabling minimally invasive, long-term monitoring and modulation of neural circuits in vivo. Researchers can study neural dynamics with unprecedented spatial and temporal resolution while delivering pharmacological perturbations in situ. This combination helps unravel complex brain networks and their dysfunctions, potentially accelerating the discovery of novel therapeutic targets.

Another facet that enhances the technology’s viral potential is its modularity and scalability. The micropump system can be adapted to deliver a variety of therapeutic molecules ranging from small-molecule drugs to larger biomolecules like peptides and nucleic acids. Moreover, the wireless control architecture is compatible with emerging digital health platforms, facilitating integration with wearable devices and cloud-based health monitoring systems. This expansive versatility positions the system as a foundational technology for next-generation bioelectronic medicine.

The clinical translation roadmap for this neural interface includes rigorous biocompatibility assessments, chronic implantation studies, and human trials to validate safety, efficacy, and long-term stability. Initial animal models have demonstrated promising results in effective drug delivery and neural signal fidelity, encouraging optimism for upcoming phases. Collaboration between engineers, neuroscientists, clinicians, and industry partners will be vital to navigate regulatory pathways and bring this transformative platform from bench to bedside.

Importantly, the multidisciplinary team behind this innovation represents a confluence of expertise in flexible electronics, microfluidics, neuroengineering, and wireless communication technologies. Their collaborative effort highlights the power of cross-disciplinary innovation in addressing complex biomedical challenges. By pushing the boundaries of material science and microscale engineering, they have crafted a device that elegantly bridges biological and technological domains.

Public health implications of this technology are profound. The burden of neurodegenerative and neurological disorders is increasing globally, with many patients suffering from inadequate therapeutic options due to delivery constraints and side effects. This soft neural interface offers a potential solution that is not only more effective but also patient-friendly and adaptable to diverse clinical contexts. If adopted widely, it could greatly enhance patient autonomy and reduce healthcare costs by reducing hospitalization and improving disease management.

In summary, the development of a soft neural interface integrated with a tapered peristaltic micropump for wireless drug delivery marks a watershed moment in biomedical engineering. By uniting flexibility, precision, wireless communication, and biocompatibility, this platform sets a new benchmark in implantable therapeutic systems. It encapsulates the forefront of innovation aimed at transforming the future landscape of personalized medicine, neural therapy, and bioelectronic health technologies, offering hope for millions worldwide suffering from challenging neurological conditions.

Subject of Research: Soft neural interfaces and wireless drug delivery systems

Article Title: A soft neural interface with a tapered peristaltic micropump for wireless drug delivery

Article References:
Lee, H., Song, S., Ha, J. et al. A soft neural interface with a tapered peristaltic micropump for wireless drug delivery. npj Flex Electron 9, 85 (2025). https://doi.org/10.1038/s41528-025-00463-y

Image Credits: AI Generated